Metagenomi Therapeutics, Inc.
MGX
$1.46
-$0.02-1.35%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 3.72% | -8.63% | -85.38% | 0.43% | -21.27% |
| Total Depreciation and Amortization | -11.02% | -2.93% | 1.99% | 6.68% | 21.65% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -64.68% | 3.82% | 35.91% | -36.85% | 492.91% |
| Change in Net Operating Assets | 59.59% | 55.11% | 61.75% | 79.12% | -253.36% |
| Cash from Operations | 10.39% | 20.22% | 19.23% | 23.48% | -27.60% |
| Capital Expenditure | 74.55% | 93.83% | 80.90% | 68.52% | 80.77% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 12.37% | 454.76% | 254.89% | 126.66% | -53.70% |
| Cash from Investing | 13.39% | 406.28% | 246.30% | 126.10% | -52.92% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | 61.99% | 91.83% | -100.09% | 100.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 291.98% | 116.42% | 94.33% | 104.75% | -94.14% |